They did PR this about the receptor occupancy test
Post# of 148343
https://www.cytodyn.com/newsroom/press-releas...-occupancy
CytoDyn Finalizes Development of Receptor Occupancy Test to Guide Pivotal Monotherapy Discussions With the FDA
Quote:
In addition, the response rate for the first 10 weeks of leronlimab monotherapy in HIV patients has approximated 95% with the 525 mg dosage. Identifying the patients who can respond to leronlimab monotherapy at the screening is critical for therapeutic success. As such, the development of the Receptor Occupancy Test is a significant milestone that may further increase the monotherapy response rate.
“The development of the Receptor Occupancy Test is an important milestone for CytoDyn because it may allow more precise screening for leronlimab monotherapy,” stated CytoDyn President and CEO, Nader Pourhassan, Ph.D. .